John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX®

Endo, Inc. Pennsylvania

or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Elway and Ms. Wenstrup, and any statements relating to product efficacy, treatments or indications, therapeutic outcomes or treatment responses, safety or adverse reactions, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which we may not currently be able to predict. Although we believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, changes in legislation or regulations, our ability to obtain and maintain adequate protection for our intellectual property rights, the impacts of competition such as those related to XIAFLEX, unfavorable safety or efficacy data, compliance with regulatory obligations, uncertainties and timing of the regulatory approval process, unexpected claims, litigation or other disputes, our ability to successfully implement and execute on our strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.

Logo - https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/john-elway-teams-up-with-endo-to-share-update-on-dupuytrens-contracture-and-treatment-with-xiaflex-collagenase-clostridium-histolyticum-302310681.html